GSE48812 sulforaphane 4 v 10 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE48812_sulforaphane_4_v_10_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE48812_sulforaphane_4_v_10_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE48812_sulforaphane_4_v_10_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE48812_sulforaphane_4_v_10_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

Rho GTPase activating protein 23

Gene

small nucleolar RNA host gene 29

Gene

CDH13 antisense RNA 2

Gene

zinc finger protein 542, pseudogene

Gene

ribosomal protein S2 pseudogene 5

Gene

long intergenic non-protein coding RNA 707

Gene

long intergenic non-protein coding RNA 958

Gene

CENPB DNA-binding domain containing 1, pseudogene

Gene

long intergenic non-protein coding RNA 1679

Gene

MIR205 host gene

  • Gene

    Rho GTPase activating protein 23


  • Gene

    small nucleolar RNA host gene 29


  • Gene

    CDH13 antisense RNA 2


  • Gene

    zinc finger protein 542, pseudogene


  • Gene

    ribosomal protein S2 pseudogene 5


  • Gene

    long intergenic non-protein coding RNA 707


  • Gene

    long intergenic non-protein coding RNA 958


  • Gene

    CENPB DNA-binding domain containing 1, pseudogene


  • Gene

    long intergenic non-protein coding RNA 1679


  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.